AN EXPLORATION OF THE VALUE CHAIN AND ISSUES DURING COVID-19 VACCINE DEVELOPMENT

dc.contributor.authorTameka Womack
dc.contributor.authorCarin Lightner-Laws
dc.date.accessioned2024-05-21T13:41:17Z
dc.date.available2024-05-21T13:41:17Z
dc.description.abstractDuring a pandemic, the time frame to develop a vaccine shrinks to merely 5-9 months. Countries are shortening the normal value chain for vaccine development to mitigate the death toll during a global health crisis. An expedited process, politics, varying distribution priorities, Phase 1, 2 & 3 testing disparities, minimal oversight, financial incentives and a lack of transparency are all issues that impact trust and the quality of a vaccine. The value chain for developing a COVID-19 vaccine is explored along with possible ethical/quality issues that could arise during this process. Descriptive statistics, chi-square tests and results from Marascuilo pairwise comparison procedures were used to analyze surveys about trust, concerns and vaccinations amid a pandemic. The results indicate that more respondents were worried about getting COVID-19 than getting the seasonal flu and that respondents from the US were less willing to get a COVID-19 vaccine as compared with other countries.
dc.identifier.urihttps://hdl.handle.net/20.500.12951/1064
dc.titleAN EXPLORATION OF THE VALUE CHAIN AND ISSUES DURING COVID-19 VACCINE DEVELOPMENT
dc.typeJournal Article, Academic Journal
dcterms.bibliographicCitationQuarterly Review of Business Disciplines, (August 2021)
Files
Collections